SageGuard Financial Group LLC Acquires Shares of 14,280 Merck & Co., Inc. $MRK

Key Points

• SageGuard Financial Group LLC acquired a new stake of 14,280 shares of Merck in Q4, valued at approximately $1.50 million, as institutional investors now own about 76.07% of the stock.
• Analyst sentiment is broadly positive with a MarketBeat consensus of “Moderate Buy” and a consensus price target of $128.47, while several firms have raised targets up to $150.
• Company news is mixed: the FDA granted priority review for KEYTRUDA combinations and the EU approved ENFLONSIA for infant RSV protection, but a Phase 3 LITESPARK‑012 trial failed its primary endpoints, creating a near‑term pipeline setback and share pressure.

SageGuard Financial Group LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 14,280 shares of the company's stock, valued at approximately $1,503,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC raised its holdings in Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock valued at $26,000 after acquiring an additional 216 shares in the last quarter. Barnes Dennig Private Wealth Management LLC increased its holdings in Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after buying an additional 266 shares during the period. United Financial Planning Group LLC bought a new position in Merck & Co., Inc. in the 3rd quarter valued at about $31,000. Wealth Watch Advisors INC bought a new position in Merck & Co., Inc. in the 3rd quarter valued at about $34,000. Finally, Deane Retirement Strategies Inc. bought a new position in Merck & Co., Inc. in the 3rd quarter valued at about $35,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on MRK shares. Barclays started coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price on the stock. JPMorgan Chase & Co. raised their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a report on Monday, April 6th. TD Cowen raised their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a report on Friday, February 13th. Finally, Wall Street Zen raised Merck & Co., Inc. from a "hold" rating to a "buy" rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $128.47.

Merck & Co., Inc. Stock Down 1.6%

MRK stock opened at $117.15 on Tuesday. The stock has a market capitalization of $289.34 billion, a P/E ratio of 16.09, a price-to-earnings-growth ratio of 2.39 and a beta of 0.26. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The firm has a 50-day moving average price of $119.11 and a 200-day moving average price of $106.32.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to analysts' expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 4.93 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were issued a $0.85 dividend. The ex-dividend date of this dividend was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.'s dividend payout ratio is 46.70%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted priority review for two supplemental BLAs for KEYTRUDA (and KEYTRUDA QLEX) in combination with Padcev for cisplatin-eligible muscle‑invasive bladder cancer — a regulatory acceleration that can expand KEYTRUDA’s label and near‑term revenue potential. FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX with Padcev
• Positive Sentiment: European Union approves ENFLONSIA (RSV monoclonal antibody) to protect infants during their first RSV season — adds a near‑term revenue driver in prophylaxis and diversifies pediatric portfolio. Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV
• Neutral Sentiment: Market commentary and valuation pieces highlight Merck’s recent outperformance (one‑year gains) and short‑term pullbacks — useful context for positioning but not new company fundamentals. 3 Reasons We Love Merck (MRK)
• Negative Sentiment: Merck and Eisai said the Phase 3 LITESPARK‑012 combination regimens for certain first‑line advanced renal cell carcinoma failed to meet key primary endpoints — a material pipeline setback for MRK’s kidney‑cancer franchise and a driver of today’s downside pressure. Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
• Negative Sentiment: Merck/Eisai corporate update on the Phase 3 LITESPARK‑012 trial acknowledges the miss and signals additional data review; this will prompt investor focus on secondary endpoints, label prospects, and any impact to long‑term guidance. Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial

Insider Activity at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of the company's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares in the company, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the company's stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the transaction, the chief marketing officer owned 80,615 shares of the company's stock, valued at $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.